Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04374877 · ClinicalTrials.gov registry record · Phase 1
Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Coherus Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 145
- Enrollment target
NCT04374877 is a Phase 1 study that has completed, run by Coherus Oncology. The registered enrollment target is 145 participants.
The verdict
NCT04374877, a Phase 1 study, has completed, sponsored by Coherus Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 145 participants
- Enrollment target
Study Summary
This is a Phase 1/1b, open-label, first-in-human, dose-escalation and expansion study of CHS-388, a monoclonal antibody that targets IL-27, as a monotherapy and in combination in patients with solid tumors.
Interventions
- DRUG Pembrolizumab
- DRUG Toripalimab
- DRUG CHS-388
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2020-04-22 |
| Est. Completion | 2025-06-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04374877
The ClinicalTrials.gov registry entry for NCT04374877 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 145 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Coherus Oncology, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT04374877 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04374877 about?
NCT04374877 is a clinical study titled "Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors". This is a Phase 1/1b, open-label, first-in-human, dose-escalation and expansion study of CHS-388, a monoclonal antibody that targets IL-27, as a monotherapy and in combination in patients with solid tumors.
What is the current status of trial NCT04374877?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 145 participants. The study started on 2020-04-22. Estimated completion is 2025-06-05.
What interventions are being tested in trial NCT04374877?
The interventions under investigation include: Pembrolizumab (DRUG), Toripalimab (DRUG), CHS-388 (DRUG).
Who is sponsoring clinical trial NCT04374877?
This trial is sponsored by Coherus Oncology, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.